Health Canada approves new use for brentuximab vedotin

Print Friendly, PDF & Email


Brentuximab vedotin
Photo from Business Wire
Health Canada has issued a non-conditional marketing authorization for brentuximab vedotin (Adcetris). This means the drug is now approved for use as consolidation after autologous stem cell transplant (ASCT) in patients with Hodgkin lymphoma (HL) who have an increased risk of relapse or progression. Brentuximab vedotin previously received... [Read Article]
Print Friendly, PDF & Email

Nivolumab for long-term treatment of cHL after auto-HSCT

Print Friendly, PDF & Email


Micrograph showing HL
Nivolumab can provide long-term treatment for a broad range of adults who have relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous hematopoietic stem cell transplant (auto-HSCT), according to a presentation at the 14th International Conference on Malignant Lymphoma (ICML). In the phase 2 CheckMate-205 study, cHL patients achieved... [Read Article]
Print Friendly, PDF & Email

Single-dose NEPA found non-inferior to aprepitant/granisetron

Print Friendly, PDF & Email


Nurse hanging bags
of chemotherapy drugs
Photo by Bill Branson
In a head-to-head study comparing a single-dose oral antiemetic to a 3-day oral regimen, the single dose has shown itself to be non-inferior to the multi-day regimen in preventing chemotherapy-induced nausea and vomiting (CINV). The investigators evaluated netupitant/palonosetron (NEPA) against aprepitant/granisetron (APR/GRAN) in patients on... [Read Article]
Print Friendly, PDF & Email

Less is more in PET-negative, advanced HL

Print Friendly, PDF & Email


Cancer patient receiving chemotherapy
Photo by Rhoda Baer
Patients with advanced Hodgkin lymphoma (HL) who are PET-negative after initial treatment with 2 cycles of eBEACOPP* should only receive 2 additional cycles of the therapy, new research suggests. In the HD18 trial, PET-2-negative patients who received 4 cycles of eBEACOPP had non-inferior progression-free survival... [Read Article]
Print Friendly, PDF & Email

Brentuximab meets phase 3 primary endpoint in frontline advanced HL

Print Friendly, PDF & Email


Micrograph showing HL
Brentuximab vedotin (Adcetris®) in combination with a 3-drug chemotherapy regimen has met its primary endpoint of statistically significant improvement in modified progression-free survival (mPFS) compared with standard therapy in frontline treatment of advanced stage Hodgkin lymphoma (HL). The ECHELON-1 trial tested brentuximab vedotin plus Adriamycin, vinblastine, and dacarbazine (AVD) against Adriamycin, bleomycin,... [Read Article]
Print Friendly, PDF & Email